# A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma

> **NCT07472790** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing Bio-Targeting Therapeutics Technology Co., Ltd** · enrollment: 15 (estimated)

## Conditions studied

- High-grade Glioma

## Interventions

- **BIOLOGICAL:** Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）

## Key facts

- **NCT ID:** NCT07472790
- **Lead sponsor:** Beijing Bio-Targeting Therapeutics Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472790, "A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07472790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*